Last reviewed · How we verify
ENERGI-F703 GEL
ENERGI-F703 is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery.
ENERGI-F703 is a topical gel formulation designed to promote wound healing and tissue regeneration through growth factor delivery. Used for Chronic wounds and ulcers (diabetic foot ulcers, pressure ulcers, venous leg ulcers).
At a glance
| Generic name | ENERGI-F703 GEL |
|---|---|
| Sponsor | Energenesis Biomedical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Wound Care |
| Phase | Phase 3 |
Mechanism of action
The drug delivers bioactive factors in a gel matrix to the wound site, promoting angiogenesis, collagen deposition, and epithelialization. The gel formulation provides sustained release and maintains a moist wound environment conducive to healing. This approach aims to accelerate closure of chronic or difficult-to-heal wounds.
Approved indications
- Chronic wounds and ulcers (diabetic foot ulcers, pressure ulcers, venous leg ulcers)
Common side effects
Key clinical trials
- A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer (PHASE3)
- A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENERGI-F703 GEL CI brief — competitive landscape report
- ENERGI-F703 GEL updates RSS · CI watch RSS
- Energenesis Biomedical Co., Ltd. portfolio CI